The latest price target for Adverum Biotechnologies (NASDAQ:ADVM) was reported by Truist Securities on August 14, 2024. The analyst firm set a price target for $40.00 expecting ADVM to rise to within 12 months (a possible 445.70% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Adverum Biotechnologies (NASDAQ:ADVM) was provided by Truist Securities, and Adverum Biotechnologies maintained their buy rating.

The last upgrade for Adverum Biotechnologies Inc happened on August 11, 2023 when Chardan Capital raised their price target to $4. Chardan Capital previously had a neutral for Adverum Biotechnologies Inc.

There is no last downgrade for Adverum Biotechnologies.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adverum Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adverum Biotechnologies was filed on August 14, 2024 so you should expect the next rating to be made available sometime around August 14, 2025.

While ratings are subjective and will change, the latest Adverum Biotechnologies (ADVM) rating was a maintained with a price target of $60.00 to $40.00. The current price Adverum Biotechnologies (ADVM) is trading at is $7.33, which is out of the analyst’s predicted range.